stockrow
Saturday 7 November 2026
Export IAM’s income statement to Excel — free account
Iambic Therapeutics, Inc.
10.20
1.44
−12.37%
Follow IAM
Alert me
Iambic Therapeutics, Inc. (IAM) P/E ratio
P/E ratio, daily
Annual newest first
| Period | P/E ratio | Change |
|---|
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| BCAX Bicara Therapeutics Inc. compare | n/m |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | n/m |
| ENTX Entera Bio Ltd. compare | n/m |
| NVCT Nuvectis Pharma, Inc. compare | n/m |
| ACRS Aclaris Therapeutics, Inc. compare | n/m |
| APMD Apnimed, Inc. compare | 0.8× |
| VALN Valneva SE Sponsored ADR compare | 59.3× |
| ANL Adlai Nortye Ltd. Sponsored ADR compare | — |
| IAM Iambic Therapeutics, Inc. | — |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)